Alex Keun Mo Yang Purchases 88,453 Shares of Polaryx Therapeutics (NASDAQ:PLYX) Stock

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) CEO Alex Keun Mo Yang acquired 88,453 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were bought at an average price of $4.07 per share, with a total value of $360,003.71. Following the completion of the purchase, the chief executive officer owned 24,233,249 shares in the company, valued at $98,629,323.43. The trade was a 0.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Polaryx Therapeutics Stock Up 7.2%

Shares of PLYX opened at $3.27 on Friday. The stock’s fifty day moving average is $5.02. Polaryx Therapeutics, Inc. has a 12 month low of $2.07 and a 12 month high of $48.91.

Polaryx Therapeutics (NASDAQ:PLYX) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.03) EPS for the quarter.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PLYX. Weiss Ratings began coverage on Polaryx Therapeutics in a research report on Friday, April 24th. They set a “sell (e-)” rating for the company. Maxim Group began coverage on Polaryx Therapeutics in a research report on Friday, February 27th. They set a “buy” rating and a $10.00 price target for the company. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $10.00.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.